Eculizumab is a first-in-class terminal complement inhibitor which works by electively inhibiting activation of specific proteins in the complement system (c5 and c5b), which play a role in the treatment of multiple rare diseases.

Nufactor carries the following eculizumab brand:

Brand (Manufacturer)
FDA-approved indication(s)
Brand (Manufacturer):
FDA-approved indication(s):
  • Generalized myasthenia gravis (adult)
  • Neuromyelitis Optica Spectrum Disorder (adult)
  • Atypical hemolytic uremic syndrome
  • Paroxysmal nocturnal hemoglobinuria

The information provided on this website is not medical advice, nor is it intended to be a substitute for medical advice, diagnosis, and treatment. Always seek the advice of a physician or other qualified health provider with questions concerning a medical condition. Never disregard professional medical advice, or delay seeking it based on information provided on this website.